TSLP and allergic asthma: Intranasal, therapeutic administration of IFNL2/3 in a murine model of Th2-driven allergic asthma mitigated lung pathology and diminished levels of epithelial secreted Th2 cytokines, thymic stromal lymphopoietin (TSLP) and IL-33 in the bronchoalveolar lavage fluid (26).